Trials / Completed
CompletedNCT05245539
Trial to Study the Effect of CVL-231 on 24-Hour Ambulatory Blood Pressure in Participants With Schizophrenia
A Randomized, Double-Blind Trial to Study the Effect of CVL-231 on 24-Hour Ambulatory Blood Pressure in Participants With Schizophrenia
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 151 (actual)
- Sponsor
- Cerevel Therapeutics, LLC · Industry
- Sex
- All
- Age
- 30 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this trial is to characterize the effects of 2 oral doses (over 8 weeks total) of CVL-231 on ambulatory blood pressure and heart rate in patients with stable schizophrenia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CVL-231 | CVL-231 is a brain penetrant mAChR activator that selectively binds to the M4 mAChR subtype while sparing other muscarinic receptor subtypes (M1, M2, M3, and M5). CVL-231 is being developed for treatment of psychosis in schizophrenia. |
Timeline
- Start date
- 2022-01-24
- Primary completion
- 2022-10-19
- Completion
- 2022-11-14
- First posted
- 2022-02-18
- Last updated
- 2022-12-14
Locations
10 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05245539. Inclusion in this directory is not an endorsement.